Renovion is a clinical-stage pharmaceutical company developing ARINA-1, a nebulized therapy designed to restore mucus clearance and reduce inflammation in the lungs. ARINA-1 is delivered via an optimized eFlow® investigational nebulizer (PARI Pharma) and has shown patient and laboratory evidence of significant mucus clearance and a strong safety profile. The company has been granted orphan designation for lung transplant and cystic fibrosis and plans a Phase 2/3 pivotal trial in lung transplant scheduled to start in early 2021, followed by clinical programs in CF and non-CF bronchiectasis. Renovion completed an $8.1 million Series A financing to fund development and its clinical programs. Patient and lab data cited in the announcement indicate ARINA-1 augments mucus transport in CF cells and was substantially more effective than hypertonic saline in those studies. The company is focused on addressing the cycle of mucus and inflammation that drives high hospitalization and mortality in these diseases.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2020